Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB,
which encodes haemoglobin subunit β. The incidence is estimated to be between 300,000 …

Ischemia and reperfusion–elicited tissue injury contributes to morbidity and mortality in a
wide range of pathologies, including myocardial infarction, ischemic stroke, acute kidney …

Abstract Treatment of sickle cell disease (SCD) is hampered by incomplete understanding of
pathways linking hemolysis to vaso-occlusion. We investigated these pathways in …

Although the root cause of sickle cell disease is the polymerization of hemoglobin S (HbS) to
form fibers that make red cells less flexible, most drugs currently being assessed in clinical …

For over 100 years, clinicians and scientists have been unravelling the consequences of the
A to T substitution in the β-globin gene that produces haemoglobin S, which leads to the …

Sickle cell disease is a very variable condition, with outcomes ranging from death in
childhood to living relatively symptom free into the 8 th decade. Much of this variability is …

Sickle cell pain includes 3 types: acute recurrent painful crises, chronic pain syndromes, and
neuropathic pain. The acute painful crisis is the hallmark of the disease and the most …

Acute chest syndrome (ACS) is a frequent cause of acute lung disease in children with sickle
cell disease (SCD). Patients may present with ACS or may develop this complication during …

Abstract Treatment of vaso-occlusive crises (VOC) or events in sickle cell disease (SCD)
remains limited to symptom relief with opioids. Animal models support the effectiveness of …

Sickle cell anaemia (SCA) is the consequence of abnormal haemoglobin production due to
an inherited point mutation in the β‐globin gene. The resulting haemoglobin tetramer is …